U.S. Markets open in 42 mins

Galectin Therapeutics, Inc. (GALT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7100+0.0700 (+2.65%)
At close: 4:00PM EDT

Galectin Therapeutics, Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
678 620 3186
http://galectintherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Joel LewisPres, CEO & DirectorN/AN/A1970
Mr. Jack W. Callicutt C.P.A., CPACFO, Treasurer & Sec.N/AN/A1967
Dr. Harold H. ShlevinConsultant & DirectorN/AN/A1950
Robert TrittGen. CounselN/AN/AN/A
Dr. Eliezer ZomerExec. VP of Manufacturing & Product Devel.N/AN/A1947
Dr. Pol F. BoudesChief Medical OfficerN/AN/A1957
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Corporate Governance

Galectin Therapeutics, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 7. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.